ArticlePharmacogenomics2022
The importance of phenoconversion when using the
Article in Pharmacogenomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Pharmacogenomics and Opioid Efficacy in Sickle Cell Disease: Is the Field Ready for Precision Prescribing?Journal of personalized medicine · 2026Review
- Impact of CYP2D6 Genotype and Inhibitor Use on Risperidone Metabolism in Children: Functional Insights Into the *17 and *29 Alleles.Clinical and translational science · 2026Article
- Pharmacogenetics of antidepressant response: a focused review on CYP2C19, CYP2D6, SLC6A4, and HTR2A polymorphisms.Frontiers in pharmacology · 2026Review
- Implementing Pharmacogenomics in Contemporary Hospital Care: Insights from Multidisciplinary Knowledge Exchange.Pharmacogenomics and personalized medicine · 2026Article
- Implementing a pragmatic clinical trial to tailor opioids for chronic pain on behalf of the IGNITE ADOPT PGx investigators.Clinical and translational science · 2024Article
- The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics.Pharmacopsychiatry · 2024Article
- Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study.International journal of clinical pharmacy · 2023Article
- Therapeutic Drug Monitoring in Children and Adolescents: Findings on Fluoxetine from the TDM-VIGIL Trial.Pharmaceutics · 2023Article
- The pharmacogenetics ofFrontiers in pharmacology · 2023Article
- CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.Expert opinion on drug metabolism & toxicology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Tweetable abstract Clinical phenoconversion needs to be incorporated when interpreting and applying
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.